关键词: 心房颤动, 非瓣膜性, 利伐沙班, 心功能不全, 高龄, 疗效, 安全性

Abstract: Objective  To analyze the clinical efficacy and safety of rivaroxabanin elderly patients with nonvalvular atrial fibrillation (NVAF) complicated with cardiac insufficiency. Methods  A total of 182 elderly NVAF patients complicated with cardiac insufficiency who were admitted to the hospital from January 2016 to January 2020 were enrolled. The patients were randomly divided into two groups,  91 cases were selected for rivaroxaban  anticoagulation as observation group,  and other 91 cases were treated with warfarin anticoagulation as control group. The adverse events including thrombotic events,  hemorrhage,  and coagulation, as well as the coagulation function and cardiac function were recorded during the followup in two groups. Results  The total bleeding events in observation group were  significantly lower than those in control group. NTproBNP  of observation group significantly decreased compared with that of control group after  treatment. COX risk model found  that the age and warfarin were risk factors for adverse events. Conclusion  Rivaroxaban is not inferior to warfarin in treating the elderly NVAF  patients complicated with cardiac insufficiency,  but  its  safety is significantly higher than that of warfarin.

Key words: atrial fibrillation, nonvalvular; , rivaroxaban, cardiac insufficiency; , the elderly; , efficacy, safety